Jennifer Jarrett - 06 Oct 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Operating Officer
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
06 Oct 2025
Net transactions value
-$688,674
Form type
4
Filing time
08 Oct 2025, 19:08:18 UTC
Previous filing
10 Jun 2025
Next filing
12 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jarrett Jennifer Chief Operating Officer C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD /s/ Carolyn Tang, Attorney-in-Fact 08 Oct 2025 0001671311

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Options Exercise $15,345 +12,500 +5.8% $1.23 226,732 06 Oct 2025 Direct F1, F2
transaction RCUS Common Stock Sale $181,801 -12,500 -5.5% $14.54 214,232 06 Oct 2025 Direct F1, F2, F3
transaction RCUS Common Stock Options Exercise $46,393 +37,792 +18% $1.23 252,024 08 Oct 2025 Direct F1, F2
transaction RCUS Common Stock Sale $568,611 -37,792 -15% $15.05 214,232 08 Oct 2025 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (Right to Buy) Options Exercise $0 -12,500 -6.9% $0.000000 168,666 06 Oct 2025 Common Stock 12,500 $1.23 Direct F1, F5
transaction RCUS Stock Option (Right to Buy) Options Exercise $0 -37,792 -22% $0.000000 130,874 08 Oct 2025 Common Stock 37,792 $1.23 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 The option is fully vested and currently exercisable.